Paclitaxel: An effective antineoplastic agent in the treatment of xenotransplanted hepatoblastoma

Medical and Pediatric Oncology

Volumn 32, Issue 3, 1999, Pages 209-215

  Fuchs, Jörg ^a   Habild, Götz ^a   Leuschner, Ivo ^b   Schweinitz, Dietrich V ^a   Haindl, Johann ^a   Knop, Erich ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Hepatoblastoma; Immunodeficient mice; Paclitaxel; Xenografts

Indexed keywords

CARBOPLATIN; CISPLATIN; COLCHICINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; VINCA ALKALOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HEPATOBLASTOMA; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; TUMOR LOCALIZATION; TUMOR VOLUME; XENOGRAFT; XENOTRANSPLANTATION;

ALPHA-FETOPROTEINS; ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DIVISION; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; FEMALE; HEPATOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LIVER NEOPLASMS; MICE; MICE, NUDE; PACLITAXEL; TRANSPLANTATION, HETEROLOGOUS; TUBULIN;

EID: 0033011556     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199903)32:3<209::AID-MPO8>3.0.CO;2-0     Document Type: Article

References (36)

1. Wani M, Taylor H, Wall M, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileucemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-2327.
2. Rowinsky E. Update on the antitumor activity of paclitaxel in clinical trials. Ann Pharmacother 1994;28:S18-S22.
3. Sonnichsen DS, Hurwitz CA, Pratt CB, et al. Saturable pharmakokinetics and paclitaxel pharmacodyamics in children with solid tumors. J Clin Oncol 1994;12:532-538.
4. Hurwitz CA, Relling MV, Weitmann SD, et al. Phase I trials of paclitaxel in children with refractory solid tumors: a pediatric oncology group study. J Clin Oncol 1993;11:2324-2329.
5. Seibel NL, Reaman GH. New microtubular agent in pediatric oncology. Invest New Drugs 1996;14:49-54.
6. King D, Ortega J, Campell J. The surgical management of children with incompletely resected hepatic cancer is facilitated by intensive chemotherpay. J Pediatr Surg 1991;26:1074-1981.
7. Schweinitz D, Hecker H, Bürger D, et al. Chirurgische Therapie von Hepatoblastomen im Kindesalter. Langenbecks Arch Chir 1995;380:315-320.
8. Schweinitz D, Hecker H, Schmidt V, et al. Prognostic factors and staging system in childhood hepatoblastoma. Int J Cancer 1997; 74:593-599.
9. Stringer M, Hennayke S, Howard E, et al. Improved outcome for children with hepatoblastoma. Brit J Surg 1995;82:386-391.
10. Reynolds M. Conversion of unresectable to resectable hepatoblastoma and long-term follow-up study. World J Surg 1995;19:814-816.
11. Exelby P, Filler R, Grosfeld J. Liver tumors in children in the particular reference to hepatoblastoma and hepatocellular carcinoma: American Academy of Pediatrics Surgical Section Survey, 1974. J Pediatr Surg 1975;10:329-337.
12. Reynolds M, Douglass E, Finegold M. Chemotherapy can convert unresectable hepatoblastoma. J Pediatr Surg 1992;27:1080-1084.
13. Filler R, Ehrlich P, Grennberg M. Preoperative chemotherapy in hepatoblastoma. Surgery 1992;110:519-522.
14. Fuchs J, Schmidt D, Pietsch T, et al. Successful transplantation of human hepatoblastoma into immunodeficient mice. J Pediatr Surg 1996;31:1241-1249.
15. Pietsch T, Fonatsch C, Albrecht S, et al. Characterisation of the continous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 1996;74:809-817.
16. Schweinitz D, Bürger D, Weinel P, et al. The treatment of malignant liver tumors in childhood: an interim report of the multicentric study HB-89 of the GPOH. Klin Pädiatr 1992;204:214-220.
17. Schweinitz D, Fuchs J, Mildenberger H. Die chirurgische Strategie bei kindlichen Lebertumoren. Langenbecks Arch Chir Suppl 1996;11:1091-1094.
18. Riondel J, Jacrot M, Picot F, et al. Therapeutic response to taxol of six human tumors xenografted into nude mice. Cancer Chemother Pharmacol 1986;17:137-142.
19. Kalbfleisch J, Prentice R. The statistical analysis of failure time data. New York: John Wiley and Sons; 1980.
20. Wynford-Thomas D, Williams ED. Use of bromodeoxyuridine for cell kinetic studies in intact animals. Cell Tissue Kinet 1986;19: 179-182.
21. Cordell J, Falini B, Erber W. et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase. J Histochem Cytochem 1974;32:219-229.
22. Ishak K, Glunz P. Hepatoblastoma and hepatocarcinoma in infancy and childhood. Cancer 1967;20:396-422.
23. Schweinitz D, Leuschner I, Glüer S, et al. Expression of cell adhesions molecules and common acute lymphablastic leukaemia antigen in hepatoblastoma. Virchows Arch 1996;429:235-241.
24. Rowinsky E, Ornetto N, Canetta R. et al. Taxol: the first of the taxanes, an imortant new class of antitumor agents. Semin Oncol 1992; 19:646-662.
25. Ninane J. Perilongo G, Stalens J. Effectiveness and toxicity of cisplatin and doxorubicin (PLADO) in childhood hepatoblastoma and hepatocellular carcinoma: a SIOP pilot study. Med Pediatr Oncol 1991;19:199-203.
26. Schweinitz D, Hecker H, Harms D. Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma. J Pediatr Surg 1995;30:845-852.
27. Saxena R, Leake J, Shafford E. Chemotherapy effects on hepatoblastoma. Am J Surg Pathol 1993;17:1266-1271.
28. Lockwood L, Heney D, Giles G, et al. Cisplatin-resistant metastatic hepatoblastoma: complete response to carboplatin, etoposide, and liver transplantation. Med Pediatric Onc 1993;21:517-520.
29. Rousseau-Merk M, Bigel P, Mouly H. Transplantability in nude mice of embryonic and other childhood tumours. Br J Cancer 1985;52:197-283.
30. Neely J, Ballard E, Britt A. Characterises of 85 pediatric tumors heterotransplanted into nude mice. Exp Cell Biol 1983;51:217-227.
31. Giovanella B, Fogh J. The nude mice in cancer research. Adv Cancer Res 1995;44:69-120.
32. Abenoza P, Manivel C, Wick R. Hepatoblastoma: an immunohistochemical and ultrastructural study. Hum Pathol 1986;18: 1025-1035.
33. Fuchs J, Wenderoth M, Schweinitz D, et al. Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma. Cancer 1998;83:2400-2407.
34. Fuchs J, Wenderoth M, Leuschner I, Schweinitz D. Comparison of the antitumor activity of cisplatin, ifosfamide, adriablastin, carboplatin and VP 16 against 3 heterotransplanted hepatoblastoma. Med Pediatr Oncol 1996;27:257.
35. Hare C, Elion G, Houghton P, et al. Therapeutic efficancy of the topoisomerase I inhibitor 7-ethyl-10-(4-(1-piperidino)-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous systems tumor xenografts. Cancer Chemother Pharmacol 1997;39:187-191.
36. Crist W. Development of new agents for treatment of rhabdomyosarcoma. Proc 3rd Int Soft Tissue Sarcoma Congr 1997;60-61.